Healthcare Business Update: Merck Pays Milestone to Ligand, Alnylam Partners with Genzyme
Merck & Co. (NYSE:MRK) will pay a $2 million milestone payment to Ligand Pharmaceuticals (NASDAQ:LGND) through the terms of a development and license collaboration for the development of dinaciclib. The payment was triggered by the beginning of a Phase 2b/3 adaptive clinical trial for dinaciclib to treat patients suffering from refractory chronic lymphocytic leukemia.
Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>
Alnylam Pharmaceuticals (NASDAQ:ALNY) and Genzyme, a Sanofi (NYSE:SNY) business, are collaborating in the development and commercialization of RNAi therapeutics, which targets transthyretin for the treatment of transthyretin-mediated amyloidosis in Japan and in other Asia-Pacific countries.
Don’t Miss: Here’s Why Pharmaceutical Stocks are Rising Now.